the challenge really at the moment is investor boredom. in small cap biotechs, investors are in it for the clinical trial results. Goals can be kicked like formulations being ready, trial applications, sites established, etc. but the asx provide enough evidence that these announcements do nothing for share price. Especially in this market. While absolutely critical, the only news that’s gonna get this moving is licensing, partnerships and or results on clinical trials (and based on Sheba 2, I’m imagining RC220 is all investors care about).
Very exciting 2 years ahead but I can’t see many quick wins, there’s lots of other companies on the asx who are closer to revenue in biotech (CU6, BOT, DXB are a few). And look at NEU, now making 50M at least a quarter with their product, easy to think that they would be a BP takeover target plus with the new P2 results,
full faith in management now, it’ll just be a very slow road to the top I feel
the challenge really at the moment is investor boredom. in small...
-
- There are more pages in this discussion • 1,445 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.015(0.95%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.63 | $1.56 | $160.1K | 100.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 222 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |